• Operating revenue up 56% to $5.9m, with gross margins >90%
• Underlying SaaS revenue up 95% vs FY2024
• Cost reduction program delivers $6.5m in annualised savings
• Secured $10m strategic investment from Pro Medicus

4DMedical Limited (ASX:4DX) has announced its FY2025 full-year results, reporting significant advancements across its operations, including the commercialisation and global expansion of its proprietary respiratory imaging technologies, regulatory approval progress, clinical trial advancements, and organisational changes to support long-term growth. Key highlights include a 56% increase in operating revenue to $5.9m, with gross margins exceeding 90%, and a 95% rise in underlying SaaS revenue compared to FY2024. The company also initiated a cost reduction program in Q3 FY2025 that has delivered $6.5m in annualised savings. 4DMedical secured a $10m strategic investment from leading global medical imaging software company Pro Medicus (ASX:PME). The company's FDA 510(k) submission for its groundbreaking CT:VQ™ software, a non-contrast, CT-based lung imaging tool, is progressing towards clearance. 4DMedical also announced the signing of a Reseller Agreement with Philips, under which its combined product suite was added to Philips' product catalogue in Q3 FY2025. The company continued to expand its commercial footprint, with new contracts signed at key reference sites in the U.S. and Australia, as well as contract renewals with leading healthcare providers. 4DMedical is now delivering SaaS products at 388 sites globally, up 60% year-on-year, and produced over 74,000 structural and functional scans in Q4 FY2025, up 35% quarter-on-quarter and 105% year-on-year.

In FY2025, 4DMedical reported operating revenue of $5.9m, up 56% from FY2024, with gross margins exceeding 90%. The company's underlying SaaS revenue increased 95% compared to the prior year.

4DMedical is poised for strong performance in the coming months and throughout FY2026, with the rapid growth in sites and scans, the growing momentum in the Philips partnership, and the expected FDA clearance of its CT:VQ™ solution, which the company believes will substantially disrupt the current market for lung perfusion imaging.